Rodman & Renshaw Bullish on Bioenvision (BIVN), Says Stock Does Not Reflect Clofarabine or Buyout
More News related to BIVN
- Wachovia Starts Bioenvision (BIVN) at Market Perform
- Bioenvision (BIVN) Reports a Q4 Loss
- Bioenvision's (BIVN) Former General Counsel Files Action in NY Supreme Court Against the Company
- Genzyme (GENZ) Announces Completion of Tender Offer for Bioenvision
- Rodman & Renshaw Downgardes Bioenvision (BIVN) to Market Perform
More News related to DNA
- Piper Jaffray Reiterates an 'Overweight' on Regeneron Pharmaceuticals (REGN); Raises Price Target
- Biogen Idec (BIIB) Announces Decision By Arbitration Panel in Issues with Genentech (DNA)
- Genentech (DNA) Announces Voluntary Withdrawal of Raptiva from the U.S. Market
- FDA ODA Committee Recommends Accelerated Approval of Genentech's (DNA) Avastin for Brain Cancer
- Genentech (DNA) said FDA committee unamiously recommends accelerated approval of Avastin in brain cancer
More News related to MRK
- Merck Wins Summary Judgment in Second Federal Bellwether Case Involving FOSAMAX(R) (alendronate sodium)
- Merck (MRK) Dismissed from All Travis County VIOXX Claims
- Merck Wins Summary Judgment in Texas Attorney General's Lawsuit Involving VIOXX(R)
- Notable Midday ETF Movers 11/20: XLV, EWJ Higher; XHB, XLE, SMH Lower
- Merck Receives CHMP Positive Opinion for New Fertility Treatment, ELONVA(R)
More News related to Analyst Comments
- Pinnacle Gas (PINN) to Form Special Committee to Review Possible Proposals, Including Asset Divestitures, Equity Offerings
- Bunge (BG) To Acquire Brazilian Sugarcane Company Moema in an Estimated $1.35B Transaction
- Net 1 UEPS (UEPS) Acquires MediKredit Integrated in $10M Transaction
- Google (GOOG) Acquires San Mateo Startup Teracent
- Green Mountain Coffee Roasters Confirms $30/Share Cash Bid for Diedrich Coffee Following Raised Peet's Bid (GMCR, DDRX, PEET)
Rodman & Renshaw reiterated its positive stance on Bioenvision (Nasdaq: BIVN) in a research note titled: FISCAL 1Q07 UPDATE - BIG PHARMA/BIOTECH ON A BUYING SPREE - WHO'S NEXT?
Analyst Reni J. Benjamin said, "We are reiterating our Market Outperform / Speculative Risk rating and our 12-month target price of $12. With clofarabine on the market for pediatric ALL, a potential European filing in AML by year end, significant news flow highlighting strong clinical efficacy at upcoming conferences, and the initiation of a broad clinical program targeting large unmet needs, we believe the company’s current market valuation does not reflect the potential of clofarabine or the potential of the company as an acquisition target."
Note: Yesterday, Genentech (NYSE: DNA) announced a deal to buy Tanox Inc. (Nasdaq: TNOX) for $20 per share, a 46% premium to today's closing price. Another recent notable deal was Merck's (NYSE: MRK) deal to buy Sirna Therapeutics, Inc. (NASDAQ: RNAI), at a 100% premium.
Related Categories
Analyst CommentsRumors
Stocks Mentioned
-0.03
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
